Matt Mamak, Justin Howard, Mark McElreath, Robyn Downing, Natalie Clayton, Maddy Byrd, Mike Stevens, and Brendan Caroll are noted for representing Stemline Therapeutics in its $677 million acquisition by Menarini Group.
In the News May 4, 2020
Law360, The Deal, Global Legal Chronicle | Menarini to Buy Stemline Therapeutics
Phone: +1 212 210 1256
Phone: +1 404 881 7758
Phone: +1 212 210 9595
Phone: +1 212 210 9470
Phone: +1 212 210 9573
Phone: +1 404 881 7970
Phone: +1 202 239 3216
Related News & Insights
Press Release February 8, 2022Nuvectis Pharma Closes $16 Million Initial Public Offering of Common StockAlston & Bird client Nuvectis Pharma Inc., an oncology-focused biopharmaceutical company based in Fort Lee, NJ, has announced the closing of its initial public offering (IPO) of 3.2 million shares of common stock at a price of $5 per share, for gross proceeds of $16 million before deducting underwriting discounts and offering expenses. All shares of common stock were offered by Nuvectis.
Press Release November 18, 2021Journey Medical Closes $35.2 Million IPO of Common StockAlston & Bird client Journey Medical Corp., a pharmaceutical company based in Scottsdale, AZ, completed its initial public offering (IPO) of 3,520,000 shares of common stock at a price to the public of $10 per share for gross proceeds of $35.2 million, before deducting underwriting discounts and offering expenses. All the shares of common stock were offered by Journey Medical.
In the News February 3, 2021Global Legal Chronicle | OncoSec Medical’s $42 Million Shares OfferingMatt Mamak, Robyn Downing, Laura Giambalvo, Bryan Skelton, and Kirk Ekena are noted for representing OncoSec Medical Incorporated in a $42 million public offering of common stock.
Press Release December 21, 2020TG Therapeutics Raises $300 Million in Upsized Common Stock OfferingAlston & Bird client TG Therapeutics, a biopharmaceutical company developing novel treatments for certain blood cancers and autoimmune diseases, closed an upsized public offering of common stock that raised $300 million.
In the News June 25, 2020Global Legal Chronicle | Mustang Bio’s $40 Million Public OfferingMark McElreath, Gerard Hart, Joel Jung, Natalie Clayton, and Ravi Shah are noted for representing Mustang Bio Inc. in its $40 million public notes offering.